In multiple myeloma, a B cell-derived cancer, the over-expressed B-cell Maturation Antigen (BCMA), essential for B cell maturation, survival, and proliferation, is targetted (NCT04244656) (Rinaldi et al., 2022). Here, TNFRSF17 is linked to plasma cell myeloma.